HEADER APOPTOSIS 03-APR-12 4EHR TITLE CRYSTAL STRUCTURE OF BCL-XL COMPLEX WITH 4-(5-BUTYL-3-(HYDROXYMETHYL)- TITLE 2 1-PHENYL-1H-PYRAZOL-4-YL)-3-(3,4-DIHYDRO-2(1H)- TITLE 3 ISOQUINOLINYLCARBONYL)-N-((2-(TRIMETHYLSILYL)ETHYL)SULFONYL)BENZAMIDE COMPND MOL_ID: 1; COMPND 2 MOLECULE: BCL-2-LIKE PROTEIN 1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: UNP RESIDUES 1-209; COMPND 5 SYNONYM: BCL2-L-1, APOPTOSIS REGULATOR BCL-X; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2L1, BCL2L, BCLX; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: HMS174 (DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET29B KEYWDS APOPTOSIS, PROGRAMMED CELL DEATH, BCL-2 FAMILY EXPDTA X-RAY DIFFRACTION AUTHOR G.M.SCHROEDER,D.WEI,P.BANFI,Z.CAI,J.LIPPY,M.MENICHINCHERI,M.MODUGNO, AUTHOR 2 J.NAGLICH,B.PENHALLOW,H.L.PEREZ,J.SACK,R.J.SCHMIDT,A.TEBBEN,C.YAN, AUTHOR 3 L.ZHANG,A.GALVANI,L.J.LOMBARDO,R.M.BORZILLERI REVDAT 3 28-FEB-24 4EHR 1 REMARK SEQADV REVDAT 2 13-JUN-12 4EHR 1 JRNL REVDAT 1 06-JUN-12 4EHR 0 JRNL AUTH G.M.SCHROEDER,D.WEI,P.BANFI,Z.W.CAI,J.LIPPY,M.MENICHINCHERI, JRNL AUTH 2 M.MODUGNO,J.NAGLICH,B.PENHALLOW,H.L.PEREZ,J.SACK, JRNL AUTH 3 R.J.SCHMIDT,A.TEBBEN,C.YAN,L.ZHANG,A.GALVANI,L.J.LOMBARDO, JRNL AUTH 4 R.M.BORZILLERI JRNL TITL PYRAZOLE AND PYRIMIDINE PHENYLACYLSULFONAMIDES AS DUAL JRNL TITL 2 BCL-2/BCL-XL ANTAGONISTS. JRNL REF BIOORG.MED.CHEM.LETT. V. 22 3951 2012 JRNL REFN ISSN 0960-894X JRNL PMID 22608393 JRNL DOI 10.1016/J.BMCL.2012.04.106 REMARK 2 REMARK 2 RESOLUTION. 2.09 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.2 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.09 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.72 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.5 REMARK 3 NUMBER OF REFLECTIONS : 11303 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.235 REMARK 3 R VALUE (WORKING SET) : 0.233 REMARK 3 FREE R VALUE : 0.283 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.150 REMARK 3 FREE R VALUE TEST SET COUNT : 582 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.09 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.29 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 98.45 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2630 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2784 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2475 REMARK 3 BIN R VALUE (WORKING SET) : 0.2768 REMARK 3 BIN FREE R VALUE : 0.3023 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.89 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 155 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1085 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 52 REMARK 3 SOLVENT ATOMS : 34 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 39.94 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 45.80 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.31750 REMARK 3 B22 (A**2) : 1.31750 REMARK 3 B33 (A**2) : -2.63510 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.326 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.205 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.938 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.904 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 1168 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 1589 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 386 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 25 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 205 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 1168 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 138 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 1430 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.14 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.27 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 20.18 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4EHR COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-APR-12. REMARK 100 THE DEPOSITION ID IS D_1000071633. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 22-MAY-10 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : CLSI REMARK 200 BEAMLINE : 08ID-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.980 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RAYONIX MX-225 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 (DENZO) REMARK 200 DATA SCALING SOFTWARE : HKL-2000 (SCALEPACK) REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11425 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.090 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 12.50 REMARK 200 R MERGE (I) : 0.07700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 25.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.09 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.16 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 12.40 REMARK 200 R MERGE FOR SHELL (I) : 0.49600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 6.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.18 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.33 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 42 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -Y+1/2,X+1/2,Z+1/2 REMARK 290 4555 Y+1/2,-X+1/2,Z+1/2 REMARK 290 5555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 6555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 51.11350 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 51.11350 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 17.46450 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 51.11350 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 51.11350 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 17.46450 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 51.11350 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 51.11350 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 17.46450 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 51.11350 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 51.11350 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 17.46450 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -2 REMARK 465 SER A -1 REMARK 465 HIS A 0 REMARK 465 MET A 1 REMARK 465 PHE A 67 REMARK 465 SER A 68 REMARK 465 ASP A 69 REMARK 465 VAL A 70 REMARK 465 GLU A 71 REMARK 465 GLU A 72 REMARK 465 ASN A 73 REMARK 465 ARG A 74 REMARK 465 THR A 75 REMARK 465 GLU A 76 REMARK 465 ALA A 77 REMARK 465 PRO A 78 REMARK 465 GLU A 79 REMARK 465 GLY A 80 REMARK 465 THR A 81 REMARK 465 GLU A 82 REMARK 465 ASN A 197 REMARK 465 ASN A 198 REMARK 465 ALA A 199 REMARK 465 ALA A 200 REMARK 465 ALA A 201 REMARK 465 GLU A 202 REMARK 465 SER A 203 REMARK 465 ARG A 204 REMARK 465 LYS A 205 REMARK 465 GLY A 206 REMARK 465 GLN A 207 REMARK 465 GLU A 208 REMARK 465 ARG A 209 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 26 CG CD OE1 NE2 REMARK 470 GLU A 84 CG CD OE1 OE2 REMARK 470 GLN A 88 CG CD OE1 NE2 REMARK 470 GLU A 96 CG CD OE1 OE2 REMARK 470 ARG A 103 NE CZ NH1 NH2 REMARK 470 GLN A 111 CG CD OE1 NE2 REMARK 470 GLN A 121 CG CD OE1 NE2 REMARK 470 GLU A 124 CG CD OE1 OE2 REMARK 470 ARG A 132 NE CZ NH1 NH2 REMARK 470 LYS A 157 CG CD CE NZ REMARK 470 GLU A 179 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 SER A 25 C - N - CA ANGL. DEV. = 20.1 DEGREES REMARK 500 GLN A 26 C - N - CA ANGL. DEV. = 16.8 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 25 135.78 95.08 REMARK 500 MET A 159 51.73 -104.00 REMARK 500 GLN A 160 -9.92 -58.55 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 0Q5 A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IMD A 302 DBREF 4EHR A 1 209 UNP Q07817 B2CL1_HUMAN 1 209 SEQADV 4EHR GLY A -2 UNP Q07817 EXPRESSION TAG SEQADV 4EHR SER A -1 UNP Q07817 EXPRESSION TAG SEQADV 4EHR HIS A 0 UNP Q07817 EXPRESSION TAG SEQADV 4EHR A UNP Q07817 MET 45 DELETION SEQADV 4EHR A UNP Q07817 GLU 46 DELETION SEQADV 4EHR A UNP Q07817 THR 47 DELETION SEQADV 4EHR A UNP Q07817 PRO 48 DELETION SEQADV 4EHR A UNP Q07817 SER 49 DELETION SEQADV 4EHR A UNP Q07817 ALA 50 DELETION SEQADV 4EHR A UNP Q07817 ILE 51 DELETION SEQADV 4EHR A UNP Q07817 ASN 52 DELETION SEQADV 4EHR A UNP Q07817 GLY 53 DELETION SEQADV 4EHR A UNP Q07817 ASN 54 DELETION SEQADV 4EHR A UNP Q07817 PRO 55 DELETION SEQADV 4EHR A UNP Q07817 SER 56 DELETION SEQADV 4EHR A UNP Q07817 TRP 57 DELETION SEQADV 4EHR A UNP Q07817 HIS 58 DELETION SEQADV 4EHR A UNP Q07817 LEU 59 DELETION SEQADV 4EHR A UNP Q07817 ALA 60 DELETION SEQADV 4EHR A UNP Q07817 ASP 61 DELETION SEQADV 4EHR A UNP Q07817 SER 62 DELETION SEQADV 4EHR A UNP Q07817 PRO 63 DELETION SEQADV 4EHR A UNP Q07817 ALA 64 DELETION SEQADV 4EHR A UNP Q07817 VAL 65 DELETION SEQADV 4EHR A UNP Q07817 ASN 66 DELETION SEQADV 4EHR A UNP Q07817 GLY 67 DELETION SEQADV 4EHR A UNP Q07817 ALA 68 DELETION SEQADV 4EHR A UNP Q07817 THR 69 DELETION SEQADV 4EHR A UNP Q07817 GLY 70 DELETION SEQADV 4EHR A UNP Q07817 HIS 71 DELETION SEQADV 4EHR A UNP Q07817 SER 72 DELETION SEQADV 4EHR A UNP Q07817 SER 73 DELETION SEQADV 4EHR A UNP Q07817 SER 74 DELETION SEQADV 4EHR A UNP Q07817 LEU 75 DELETION SEQADV 4EHR A UNP Q07817 ASP 76 DELETION SEQADV 4EHR A UNP Q07817 ALA 77 DELETION SEQADV 4EHR A UNP Q07817 ARG 78 DELETION SEQADV 4EHR A UNP Q07817 GLU 79 DELETION SEQADV 4EHR A UNP Q07817 VAL 80 DELETION SEQADV 4EHR A UNP Q07817 ILE 81 DELETION SEQADV 4EHR A UNP Q07817 PRO 82 DELETION SEQADV 4EHR A UNP Q07817 MET 83 DELETION SEQADV 4EHR A UNP Q07817 ALA 84 DELETION SEQRES 1 A 172 GLY SER HIS MET SER GLN SER ASN ARG GLU LEU VAL VAL SEQRES 2 A 172 ASP PHE LEU SER TYR LYS LEU SER GLN LYS GLY TYR SER SEQRES 3 A 172 TRP SER GLN PHE SER ASP VAL GLU GLU ASN ARG THR GLU SEQRES 4 A 172 ALA PRO GLU GLY THR GLU SER GLU ALA VAL LYS GLN ALA SEQRES 5 A 172 LEU ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG SEQRES 6 A 172 ARG ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR SEQRES 7 A 172 PRO GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN SEQRES 8 A 172 GLU LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL SEQRES 9 A 172 ALA PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER SEQRES 10 A 172 VAL ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE ALA SEQRES 11 A 172 ALA TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO SEQRES 12 A 172 TRP ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL GLU SEQRES 13 A 172 LEU TYR GLY ASN ASN ALA ALA ALA GLU SER ARG LYS GLY SEQRES 14 A 172 GLN GLU ARG HET 0Q5 A 301 47 HET IMD A 302 5 HETNAM 0Q5 4-[5-BUTYL-3-(HYDROXYMETHYL)-1-PHENYL-1H-PYRAZOL-4-YL]- HETNAM 2 0Q5 3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YLCARBONYL)-N-{[2- HETNAM 3 0Q5 (TRIMETHYLSILYL)ETHYL]SULFONYL}BENZAMIDE HETNAM IMD IMIDAZOLE FORMUL 2 0Q5 C36 H44 N4 O5 S SI FORMUL 3 IMD C3 H5 N2 1+ FORMUL 4 HOH *34(H2 O) HELIX 1 1 GLN A 3 LYS A 20 1 18 HELIX 2 2 GLU A 84 TYR A 101 1 18 HELIX 3 3 TYR A 101 LEU A 112 1 12 HELIX 4 4 THR A 118 PHE A 131 1 14 HELIX 5 5 ASN A 136 LYS A 157 1 22 HELIX 6 6 VAL A 161 LEU A 178 1 18 HELIX 7 7 LEU A 178 ASN A 185 1 8 HELIX 8 8 GLY A 186 GLY A 196 1 11 CISPEP 1 TRP A 24 SER A 25 0 20.35 CISPEP 2 SER A 25 GLN A 26 0 14.52 SITE 1 AC1 12 SER A 25 GLN A 26 PHE A 97 ARG A 100 SITE 2 AC1 12 TYR A 101 ALA A 104 PHE A 105 GLU A 129 SITE 3 AC1 12 LEU A 130 GLY A 138 ARG A 139 PHE A 146 SITE 1 AC2 2 GLN A 26 VAL A 163 CRYST1 102.227 102.227 34.929 90.00 90.00 90.00 P 42 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.009782 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009782 0.000000 0.00000 SCALE3 0.000000 0.000000 0.028630 0.00000